|
|
|
The BLA was submitted on August 28, 2008 for use of Menveo in subjects age 11 - 55. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products.novartis. Journal of the American Medical Association. 10th Edition, 2nd printing.--(BUSINESS WIRE)--Jul 6, 2009 - Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board:AOLS) announced today that data from a study in which AEOL 10150 was administered to 40 mice who had been exposed to radiation show a statistically significant increase in survival rates among mice who were treated with AEOL 10150 compared to controls. Untreated mice experienced a steady decline in body weight over the six weeks, while treated animals experienced weight gain that was just slightly less than that seen in the controls (animals not receiving radiation).
difference between valium and xanax find xanax without prescription here xanax and side effects xanax proper dosege xanax result time xanax treatment compare xanax to zoloft
No new clinical trials are required, and it is expected that Novartis will be able to respond to all questions fully in 2009.
About meningococcal disease
Meningococcal disease can manifest as bacterial meningitis - an infection of the protective coverings of the brain and spinal cord - or meningococcemia - a bloodstream infection[2]. You should not place undue reliance on these statements.
-- Advanced Development Stage – AEOL 10150 has demonstrated safety in three human clinical trials, and has an extensive pre-clinical safety and toxicology package completed.
-- Large scale manufacturing – Aeolus has contract capacity with a large manufacturing site to mass produce large quantities of AEOL 10150 under GMP conditions.
|
|
No News has been posted yet
|
|
|
Forgotten your password? Request a new one here.
|
 Guests Online: 1
No Members Online
Registered Members: 1
Unactivated Members: 0
Newest Member: Owen Electrical
|
|
v6.01.1 © 2003-2005